Worthwhile Stock:- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) stock traded volume of 21183 shares during its last trading session as compared to its average volume of 9327 shares over the recent month. BVXV ended its day with the below stream along the move of -3.01% and closed at the price of $6.45 before opening at $6.62. It has total market capitalization is $43461000. 52 week range of the stock remained $ 4.6 – 10.75 while its day lowest price was $6.31 and its hit its day highest price at $6.69

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, reported its financial results for the quarter ended March 31, 2018.

First Quarter 2018 Financial Summary

Results are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.514 (NIS/$US) as at March 29, 2018

First quarter operating expenses were NIS 12.6m ($3.6m) compared with NIS 2.97m for the first quarter of 2017;

First quarter R&D expenses amounted to NIS 11.7m ($3.3m) compared with NIS 1.87m for the first quarter of 2017;

As of March 31, 2018, BiondVax had cash and cash equivalents of NIS 55.7 million ($15.8 million) as compared to NIS 71.3 million as of December 31, 2017. The decrease is attributable to execution of planned ongoing operations related to launch of the pivotal, clinical efficacy, Phase 3 trial of the Company’s M-001 Universal Flu Vaccine candidate, and construction of a mid-size commercial manufacturing facility.

Nattan is a self-taught investor and follows the value investing approach to picking stocks. He possesses over 10 years of investment experience, an M.B.A. from Louisiana State University, and is also certified in Risk Management Assurance. Nattan is a Certified Internal Auditor, Data Miner, and author with a career broadly spanning over multiple business areas. He has exploited those observations and developed investment tactics within a fundamentally sound long-term investment strategy. He currently covers Earnings News category for our site.


Leave a Reply

Your email address will not be published. Required fields are marked *